Print Share Email Send Email Your Name (required) ! Example: John Doe Email Address (required) ! Error: Please enter a valid sender email address. Example: firstname.lastname@example.org CC Me Recipient Email Address (required) ! Separate multiple email address with semi-colons (up to 5). Subject Subject for your email. Message (Maximum characters: 1,000) Error: Please enter your name Error: Please enter your email address Error: Please enter a valid recipient email address. Example:email@example.com Thank you! Your email has been sent to: The recipient(s) will receive an email message that includes a link to the selected article. Recipients may need to check their spam filters or confirm that the address is safe. Return to: Send Another Email An error has occurred sending your email(s). Please try again later or contact an administrator at OnlineCustomer_Service@email.mheducation.com. Return to: Twitter Facebook Linkedin Reddit Get Citation Citation Disclaimer: These citations have been automatically generated based on the information we have and it may not be 100% accurate. Please consult the latest official manual style if you have any questions regarding the format accuracy. AMA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. Brain Cancer: Primary CNS Lymphoma: High-Dose Cytarabine. Hematology-Oncology Therapy Updates, 29 November 2018. McGraw-Hill, 2018. AccessHemOnc. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=452892§ionid=204842608APA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. (2018). Brain cancer: primary cns lymphoma: high-dose cytarabine. Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. Hematology-oncology therapy updates. McGraw-Hill. https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=452892§ionid=204842608.MLA Citation Therapy H. Therapy H Therapy, Hematology-Oncology. "Brain Cancer: Primary CNS Lymphoma: High-Dose Cytarabine." Hematology-Oncology Therapy Updates Boyiadzis MM. Boyiadzis M.M. Boyiadzis, Michael M. McGraw-Hill, 2018, https://hemonc.mhmedical.com/updatesContent.aspx?gbosid=452892§ionid=204842608. Download citation file: RIS (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley © Copyright Tools Clip Full Chapter Figures Only Tables Only Videos Only Supplementary Content Top Brain Cancer: Primary CNS Lymphoma: High-Dose Cytarabine by Hematology-Oncology Therapy Listen + +Update to Chapter 5: Brain Cancer + Chamberlain MC. J Neurooncol 2016;126:545–550 Cytarabine 3000 mg/m2 per dose; administer intravenously in 100–1000 mL 0.9% sodium chloride injection or 5% dextrose injection over 3 hours, every 12 hours for 4 doses (2 doses/day) on days 1 and 2, every 28 days, until disease progression (total dosage/cycle = 12,000 mg/m2) Note: Patients with renal dysfunction and/or elderly patients are at increased risk of high-dose cytarabine-induced cerebellar toxicity; consider initiating treatment at a reduced dose. Dose reduction recommendations vary; one commonly cited reference (Kintzel PE, Dorr RT. Cancer Treat Rev 1995;21:33–64) suggests: Creatinine clearance 46–60 mL/min: Reduce dose to 1800 mg/m2 per dose Creatinine clearance 31–45 mL/min: Reduce dose to 1500 mg/m2 per dose Creatinine clearance <30 mL/min: Consider use of alternative drug Supportive Care Antiemetic prophylaxis Emetogenic potential is MODERATE See Chapter 39 for antiemetic recommendations Hematopoietic growth factor (CSF) prophylaxis Primary prophylaxis is indicated with one of the following: Filgrastim (G-CSF) 5 mcg/kg/day, by subcutaneous injection, or Pegfilgrastim (pegylated filgrastim) 6 mg/0.6 mL, by subcutaneous injection for 1 dose Begin use from 24–72 hours after myelosuppressive chemotherapy is completed Continue daily filgrastim use until ANC ≥5000/mm3 after the leukocyte nadir Discontinue daily filgrastim use at least 24 hours before administering myelosuppressive treatment. Do not administer pegfilgrastim within 14 days before administering myelosuppressive treatment See Chapter 43 for more information Antimicrobial prophylaxis Risk of fever and neutropenia is HIGH Antimicrobial primary prophylaxis is recommended: Antibacterial—consider fluoroquinolone prophylaxis during periods of neutropenia Antifungal—fluconazole is recommended during periods of neutropenia Antiviral—antiherpes antivirals (eg, acyclovir, famciclovir, valacyclovir) See Chapter 47 for more information Keratitis prophylaxis Steroid ophthalmic drops (prednisolone 1% or dexamethasone 0.1%); administer 2 drops by intraocular instillation into each eye every 6 hours starting prior to the first cytarabine dose and continuing until 48 hours after high-dose cytarabine is completed +Patient Population Studied + A retrospective review was performed for 14 patients with recurrent primary central nervous system lymphoma (PCNSL) after having failed first-line treatment (high-dose methotrexate plus rituximab) and second-line therapy (first salvage; temozolomide in 5 patients, high-dose methotrexate plus rituximab in 5 patients, and procarbazine plus lomustine plus vincristine in 4 patients). All patients received high-dose cytarabine (3 g/m2 over a 3 hour infusion) every 12 hours for 4 treatments and then, 12 hours after the final dose of cytarabine, pegfilgrastim (6 mg). +Efficacy (N = 14) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Efficacy (N = 14) Median progression-free survival 3 months 6-month progression-free survival 0% Median overall survival 12 months +Therapy Monitoring + CBC with differential and platelet counts and comprehensive metabolic panel daily during chemotherapy Outpatient monitoring post-chemotherapy: CBC with differential, platelets, and comprehensive metabolic panel, 2–3 times weekly until counts recover Monitor for signs of cerebellar toxicity (nystagmus, dysmetria, and ataxia) before each dose of cytarabine Patients who receive high-dose cytarabine need to be closely monitored for changes in renal function. Renal dysfunction is highly correlated with an increased risk of cerebellar toxicity Response assessment: Contrast-enhanced MRI of the brain prior to each cycle of chemotherapy +Treatment Modifications + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Treatment Modifications HIGH-DOSE CYTARABINE Adverse Event Treatment Modification Fever, myalgia, bone pain, occasionally chest pain, maculopapular rash, conjunctivitis and malaise, 6–12 hours following drug administration (cytarabine or Ara-C syndrome). Corticosteroids are beneficial in treating or preventing this syndrome. If the symptoms are deemed treatable, continue therapy with cytarabine and pretreat with corticosteroids Neurologic (cerebellar) toxicity Hold cytarabine. Patients who develop CNS symptoms should not receive subsequent high-dose cytarabine. ANC <1000/mm3 or platelet count <50,000/mm3 Consider suspending or modifying doses/schedule. Note: ANC and platelet count may continue to fall after the drug is stopped and reach lowest values after drug-free intervals of 12–24 days. When definite signs of marrow recovery appear, restart therapy +Adverse Events (N = 14) + Table Graphic Jump LocationFavorite Table | Download (.pdf) | Print Adverse Events (N = 14) Grade (%)✫ Grade 1/2 Grade 3 Grade 4 Neutropenia 43 36 21 Anemia 29 57 14 Lymphopenia 43 43 14 Mucositis 43 43 14 Thrombocytopenia 21 71 7 Fatigue 43 50 7 Neutropenic fever 14 29 7 Conjunctivitis 36 21 0 Nausea 43 14 0 Infection without neutropenia 7 14 0 Encephalopathy 14 7 0 ✫According to the National Cancer Institute Common Terminology Criteria for Adverse Events Note: No treatment-related deaths were recorded and no patient discontinued therapy because of toxicity.